A Review on Deubiquitinating Enzymes as Oncodiagnostic Biomarkers

Cancer is a fatal illness that is responsible for the deaths of millions of individuals all over the globe every year. It is possible that people will be able to survive for a longer period of time as a result of early identification, staging, and individualised biomarker therapy. Proteases known as deubiquitinating enzymes are responsible for removing ubiquitin tags from proteins so that they may be broken down by the proteasome. Enzymes that deubiquitinate proteins have several purposes throughout the body. One of the numerous roles that Deubiquitinating Enzyme plays is to keep an eye on the progression of tumours. The expression of members of the deubiquitinating enzyme family was shown to be elevated in a wide range of oncocells and tissues during various stages of cancer, according to a number of investigations. Based on these findings, deubiquitinating enzymes have the potential to be exploited as a therapeutic target in cancer treatment. In this article, the functions of members of the Deubiquitinating Enzyme family, as well as ubiquitin-specific proteases and other important family members, are dissected. Our goal was to get a better understanding of the connection between the expression patterns of deubiquitinating enzymes and carcinomas so that future research might investigate the possibility of developing inhibitors and gene therapies to improve the diagnosis and prognosis of cancer.